Adagene (ADAG) Competitors

Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, community ranking, earnings, profitability and media sentiment.

Which has more volatility and risk, ADAG or CRVS?

Adagene has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Is ADAG or CRVS more profitable?

Adagene's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Corvus Pharmaceuticals	N/A	-70.71%	-45.90%

Does the media refer more to ADAG or CRVS?

In the previous week, Adagene had 23 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 27 mentions for Adagene and 4 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 0.73 beat Adagene's score of 0.48 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	5 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, ADAG or CRVS?

Adagene has higher revenue and earnings than Corvus Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$18.11M	4.64	-$18.95M	N/A	N/A
Corvus Pharmaceuticals	N/A	N/A	-$27.03M	-$0.93	-5.76

Does the MarketBeat Community prefer ADAG or CRVS?

Corvus Pharmaceuticals received 269 more outperform votes than Adagene when rated by MarketBeat users. However, 78.57% of users gave Adagene an outperform vote while only 61.91% of users gave Corvus Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Adagene	Outperform Votes 22 78.57%	Underperform Votes 6 21.43%
Corvus Pharmaceuticals	Outperform Votes 291 61.91%	Underperform Votes 179 38.09%

Do institutionals and insiders hold more shares of ADAG or CRVS?

9.5% of Adagene shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts recommend ADAG or CRVS?

Adagene presently has a consensus price target of $8.00, indicating a potential upside of 321.05%. Corvus Pharmaceuticals has a consensus price target of $12.38, indicating a potential upside of 130.88%. Given Adagene's higher possible upside, equities research analysts clearly believe Adagene is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Corvus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Summary

Corvus Pharmaceuticals beats Adagene on 8 of the 15 factors compared between the two stocks.